Levens W, Rübben H, Ingenhag W
Urology Department, University Clinic Aachen, FRG.
Eur Urol. 1989;16(5):378-81. doi: 10.1159/000471621.
20 patients with progressive metastatic renal cell carcinoma entered a trial in which the effect of a long-term 6-month regimen of recombinant interferon alpha-2b (rIFN) was studied. 15 patients were evaluable. 4 remissions were detected: 1 complete, and 3 partial. All remissions were seen within 3 months of the start of treatment. We conclude that a 3-month rIFN treatment in metastatic renal cell carcinoma is sufficient to make a distinction between responders and non-responders. A review of the recent literature supports this conclusion.
20例进行性转移性肾细胞癌患者进入一项试验，该试验研究了重组干扰素α-2b（rIFN）为期6个月的长期治疗方案的效果。15例患者可进行评估。检测到4例缓解：1例完全缓解，3例部分缓解。所有缓解均在治疗开始后的3个月内出现。我们得出结论，转移性肾细胞癌患者接受3个月的rIFN治疗足以区分反应者和无反应者。对近期文献的回顾支持这一结论。
